Special ArticleStereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline
Cited by (0)
Supplementary material for this article (http://dx.doi.org/10.1016/j.prro.2017.04.014) can be found at www.practicalradonc.org.
Conflicts of interest. Before initiating work on this guideline, all task force members completed disclosure statements and pertinent disclosures are published within this report. Where potential conflicts are detected, remedial measures to address them are taken and noted here.
MG: honoraria and travel expenses from Elekta; CK: previous research funding from Varian; KL: stock in Pfizer and Synta Pharmaceuticals; SL: previous research funding from Elekta and previous travel expenses and honoraria from Accuray; DM: previous travel expenses from Varian, previous honoraria for Augmenix; BM: research funding and travel expenses from Varian and Philips, patents with Henry Ford Health System (no royalties received), and National Cancer Institute small business grant with Humanetics; AR: research funding from Varian, Boehringer Ingelheim, and Pfizer, previous advisory board for AstraZeneca; MR: previous travel expenses from BTG, Varian, and Elekta; RT: research funding from Varian, Accuray, and Elekta.
These disclosures were reviewed by the Guidelines Subcommittee chairs (for task force chairs), the task force chairs (for task force members), and the Conflict of Interest Review Committee. They were determined to be sufficiently managed by disclosure to the task force and in this publication.
E-mail address:[email protected] (G.M.M. Videtic).